Financial Performance Overview
Novartis AG reported net sales of USD 13.1 billion for the first quarter of 2026, representing a 5% decrease in constant currencies and a 1% decline in USD. This downturn was mainly due to competitive pressures from generic medications offsetting growth in priority brands. The core operating income for the quarter stood at USD 4.9 billion, down 14% in constant currencies and 12% in USD, reflecting lower net sales and increased research and development (R&D) investments. The core operating income margin was 37.3%, while operating income fell to USD 4.2 billion, down 11% in constant currencies.
Net income for Q1 2026 was USD 3.2 billion, decreasing 13% in constant currencies. Core earnings per share (EPS) also declined by 15% in constant currencies to USD 1.99. Free cash flow decreased slightly to USD 3.3 billion compared to the previous year.
Key Growth Drivers
Despite the overall decline in net sales, several key products demonstrated significant growth, contributing positively to Novartis's performance:
- Kisqali: Sales rose 55% to USD 1.5 billion.
- Pluvicto: Sales surged 70% to USD 642 million.
- Kesimpta: Sales increased 26% to USD 1.16 billion.
- Scemblix: Achieved a 79% growth, reaching USD 433 million.
- Leqvio: Grew by 69% to USD 452 million.
- Fabhalta: Sales doubled with 103% growth to USD 169 million.
Pipeline and R&D Updates
Novartis made noteworthy progress in its R&D pipeline during the first quarter of 2026, including:
- Remibrutinib: Received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for chronic spontaneous urticaria and showed positive Phase III results in chronic inducible urticaria, with encouraging Phase II data in food allergies.
- Ianalumab: Secured FDA Breakthrough Therapy designation for Sjögren’s disease.
- Cosentyx: Obtained FDA approval for pediatric hidradenitis suppurativa and submitted regulatory filings for polymyalgia rheumatica.
- Acquisition of Avidity Biosciences: Completed the acquisition to bolster capabilities in treating neuromuscular diseases.
Capital Structure
Novartis's net debt increased to USD 38.1 billion, mainly due to cash outflows tied to mergers and acquisitions (M&A) and dividend payments. The company repurchased approximately 10.4 million shares for USD 1.6 billion as part of its share buyback program, reflecting its shareholder return strategy.
Market Reaction
Following the earnings release, Novartis's stock price declined, reflecting investor concerns over the earnings miss compared to expectations. The stock movement highlighted market sensitivity to the company’s performance amid ongoing generic competition. Analysts emphasized caution, noting the challenges Novartis faces in maintaining growth within a competitive pharmaceutical landscape.
Conclusion
Novartis AG's Q1 2026 performance was marked by a decline in financial metrics due to competitive pressures, particularly from generics. However, growth in key priority products and advancements in R&D indicate resilience. The reaffirmed 2026 financial guidance suggests a strategic focus on overcoming current challenges. The market’s reaction underscores the importance of continual monitoring and strategic initiatives as Novartis navigates a competitive and evolving sector.
Explore more exclusive insights at nextfin.ai.
